A Phase 1, Multi-center, Open-label Study of IMGN289 Administered Intravenously in Adult Patients With EGFR-positive Solid Tumors

Trial Profile

A Phase 1, Multi-center, Open-label Study of IMGN289 Administered Intravenously in Adult Patients With EGFR-positive Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 May 2015

At a glance

  • Drugs IMGN 289 (Primary)
  • Indications Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors ImmunoGen
  • Most Recent Events

    • 24 Apr 2015 Status changed from recruiting to discontinued according to an ImmunoGen media release.
    • 25 Apr 2014 Dose escalation is ongoing in this trial, according to an ImmunoGen media release.
    • 31 Jan 2014 Data presentation and/or development decisions for IMGN-289 are anticipated in the second half of 2014, according to an ImmunoGen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top